Sage Therapeutics Inc
$
184.54
-1.28 (-0.69%)
| Volume: | 286,544 | Avg Vol (1m): | 398,287 |
| Market Cap $: | 9.44 Bil | Enterprise Value $: | 8.09 Bil |
| P/E (TTM): | 0.00 | P/B: | 6.81 |
| Earnings Power Value | -169.24 |
| Net Current Asset Value | 26.15 |
| Tangible Book | 27.21 |
| Projected FCF | -6.63 |
| Median P/S Value | 154.65 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 9.8/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt | N/A | |
| Equity-to-Asset | 0.93 |
Equity-to-Asset range over the past 10 years
Min: 0.91, Med: 0.93, Max: 0.95
Current: 0.93
| |
| Interest Coverage | No Debt | N/A | |
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 53.33 |
DISTRESS
GREY
SAFE
| |
| WACC vs ROIC % |
ROIC 0%
WACC 19.83%
| ||
Profitability & Growth : 4/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -534.47 |
Operating Margin range over the past 10 years
Min: -534.47, Med: -435.61, Max: -435.61
Current: -534.47
| |
| Net Margin % | -508.82 |
Net Margin range over the past 10 years
Min: -508.82, Med: -413.06, Max: -413.06
Current: -508.82
| |
| ROE % | -43.49 |
ROE range over the past 10 years
Min: -79.92, Med: -63.94, Max: -43.49
Current: -43.49
| |
| ROA % | -40.84 |
ROA range over the past 10 years
Min: -321.6, Med: -57.81, Max: -40.84
Current: -40.84
| |
| ROC (Joel Greenblatt) % | -9303.46 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -42160.36, Med: -16925, Max: -7408.46
Current: -9303.46
| |
| 3-Year Total EBITDA Growth Rate | -60.70 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: -106.9, Med: -76.5, Max: -35.7
Current: -35.7
| |
| 3-Year EPS w/o NRI Growth Rate | -33.40 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -48.55, Max: -33.4
Current: -33.4
|
» SAGE's 30-Y Financials
Financials (Next Earnings Date: 2019-08-06)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:SAGE
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology NAICS : 325412 SIC : 2834 |
| Compare | NAS:MRNA NAS:SRPT NAS:ALNY SZSE:000661 NAS:BLUE NAS:TECH NAS:JAZZ HKSE:06160 NAS:IONS OCSE:GEN NAS:NBIX SZSE:002252 TSE:4587 NAS:AMRN XAMS:GLPG NAS:SGEN NAS:EXEL SZSE:002007 NAS:NKTR NAS:ASND |
| Traded in other countries | SG7.Germany |
| Address | 215 First Street, Cambridge, MA, USA, 02142 |
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. Sage's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 6.81 |
PB Ratio range over the past 10 years
Min: 4.45, Med: 6.41, Max: 8.74
Current: 6.81
| |
| PS Ratio | 94.61 |
PS Ratio range over the past 10 years
Min: 42.24, Med: 79.31, Max: 98.13
Current: 94.61
| |
| EV-to-EBIT | -16.70 |
EV-to-EBIT range over the past 10 years
Min: -27.6, Med: -15.3, Max: -7.4
Current: -16.7
| |
| EV-to-EBITDA | -16.73 |
EV-to-EBITDA range over the past 10 years
Min: -27.6, Med: -15.3, Max: -7.4
Current: -16.73
| |
| EV-to-Revenue | 89.13 |
EV-to-Revenue range over the past 10 years
Min: 32.3, Med: 67.2, Max: 83
Current: 89.13
| |
| Current Ratio | 20.06 |
Current Ratio range over the past 10 years
Min: 1.99, Med: 14.95, Max: 28.92
Current: 20.06
| |
| Quick Ratio | 20.06 |
Quick Ratio range over the past 10 years
Min: 1.99, Med: 14.95, Max: 28.92
Current: 20.06
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -17.00 |
3-Year Share Buyback Rate range over the past 10 years
Min: -17.9, Med: -15.6, Max: -4.9
Current: -17
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.78 |
Price-to-Tangible-Book range over the past 10 years
Min: 3.57, Med: 6.77, Max: 14.55
Current: 6.78
| |
| Price-to-Median-PS-Value | 1.19 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.63, Med: 0.97, Max: 1.24
Current: 1.19
| |
| Earnings Yield (Joel Greenblatt) % | -6.01 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -13.5, Med: -6.6, Max: -3.6
Current: -6.01
|
More Statistics
| Revenue (TTM) (Mil) $ | 90.74 |
| EPS (TTM) $ | -9.74 |
| Beta | 2.64 |
| Volatility % | 61.32 |
| 52-Week Range $ | 79.88 - 193.56 |
| Shares Outstanding (Mil) | 51.15 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |